for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Piramal Enterprises Ltd

PIRA.NS

Latest Trade

1,466.10INR

Change

5.35(+0.37%)

Volume

1,398,320

Today's Range

1,433.50

 - 

1,481.30

52 Week Range

606.85

 - 

2,001.30

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
1,460.75
Open
1,475.00
Volume
1,398,320
3M AVG Volume
48.17
Today's High
1,481.30
Today's Low
1,433.50
52 Week High
2,001.30
52 Week Low
606.85
Shares Out (MIL)
223.82
Market Cap (MIL)
326,945.20
Forward P/E
19.90
Dividend (Yield %)
0.96

Next Event

Q2 2021 Piramal Enterprises Ltd Earnings Release

Latest Developments

More

India's Piramal Enterprises June-Quarter Consol Net Profit Rises

Piramal Enterprises To Consider NCDs Issue On Private Placement Basis Amounting Up To 760 Mln Rupees

Carlyle And Piramal Pharma Sign Agreement On A 20% Strategic Growth Investment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Piramal Enterprises Ltd

Piramal Enterprises Limited (PEL) is engaged in the business of pharmaceuticals, including research and development, financial services and information management through its subsidiaries. The Company's pharmaceutical business consists of manufacturing and sale of own and traded bulk drugs and formulations. It operates through three segments: Healthcare, Financial Services and Information Management. Its Healthcare segment includes pharma solutions, critical care, consumer products and imaging. Its Financial Services segment includes wholesale lending, alternative asset management and investments in Shriram Group. Its Information Management segment is engaged in Decision Resources Group (DRG). DRG's product and services portfolio consists of data and analytics, research products and global consulting services. The Company offers its products under brands, including Saridon, Lacto Calamine, i-pill/i-know, Polycrol, Tetmosol, Untox, Stop AllerG and Throatsil.

Industry

Biotechnology & Drugs

Contact Info

10th floor, Piramal Tower

Ganpatrao Kadam Marg

Lower Parel

400070

India

+91.22.38023083

http://www.piramal.com/our-businesses/piramal-enterprises

Executive Leadership

Ajay G. Piramal

Executive Chairman of the Board

Vivek Valsaraj

President, Chief Financial Officer

Peter DeYoung

Chief Executive Officer

Swati A. Piramal

Executive Vice Chairman of the Board

Rajesh Laddha

Group Chief Financial Officer, Executive Director

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

106.3K

2019

132.2K

2020

130.7K

2021(E)

132.1K
EPS (INR)

2018

83.303

2019

94.901

2020

1.140

2021(E)

73.949
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.39
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
1,407.43
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Piramal Enterprises To Consider NCDs Issue On Private Placement Basis Amounting Up To 760 Mln Rupees

* TO CONSIDER ISSUE OF NCDS ON PRIVATE PLACEMENT BASIS AMOUNTING UP TO 760 MILLION RUPEES Source text for Eikon: Further company coverage:

Carlyle buys 20% stake in Piramal Pharma businesses

U.S.-based Carlyle Group Inc <CG.O> has agreed to buy a 20% stake in the pharmaceutical unit of Indian conglomerate Piramal Enterprises Ltd <PIRA.NS> for about $490 million, the companies said in a statement on Saturday.

BRIEF-Carlyle And Piramal Pharma Sign Agreement On A 20% Strategic Growth Investment

* THE CARLYLE GROUP LP - CARLYLE AND PIRAMAL PHARMA SIGN AGREEMENT ON A 20% STRATEGIC GROWTH INVESTMENT

BRIEF-Piramal Enterprises Approves Issue Of Secured NCDs Up To 5 Bln Rupees

* APPROVED ISSUE OF SECURED NCDS UP TO 5 BILLION RUPEES ON PRIVATE PLACEMENT BASIS Source text for Eikon: Further company coverage:

BRIEF-Piramal Enterprises To Consider NCDs Issue Of Up To 5 Bln Rupees

* TO CONSIDER & APPROVE ISSUE OF NCDS ON PRIVATE PLACEMENT OF UP TO 5 BILLION RUPEES Source text for Eikon: Further company coverage:

BRIEF-Piramal Enterprises Posts March-Quarter Consol Loss

* INDIA'S PIRAMAL ENTERPRISES MARCH-QUARTER CONSOL LOSS 17.03 BILLION RUPEES VERSUS PROFIT 4.55 BILLION RUPEES YEAR AGO

BRIEF-Piramal Enterprises Recommended A Dividend Of 14 Rupees Per Share

* PIRAMAL ENTERPRISES - DUE TO UNCERTAIN MACRO ENVIRONMENT, CREATED INR 19.03 BILLION ADDNL PROVISION Source text for Eikon: Further company coverage:

BRIEF-Piramal Enterprises Clarifies on News Article That Says KKR Likely To Pick Stake In Co

* PIRAMAL ENTERPRISES LTD REFERS TO NEWS ARTICLE ABOUT KKR LIKELY TO PICK STAKE IN CO, SAYS NO SUCH PROPOSAL RECEIVED Source text for Eikon: Further company coverage:

BRIEF-Piramal Enterprises Says Board Meeting To Consider Interim Dividend Called Off

* BOARD MEETING TO CONSIDER DECLARATION OF INTERIM DIVIDEND HAS BEEN CALLED OFF Source text for Eikon: Further company coverage:

BRIEF-Piramal Enterprises Shareholders Approve Divestment Of Healthcare Insights And Analytics Business

* SHAREHOLDERS APPROVE DIVESTMENT OF HEALTHCARE INSIGHTS AND ANALYTICS BUSINESS Source text for Eikon: Further company coverage:

Piramal Enterprises unit to divest healthcare analytics business for $950 million

Indian conglomerate Piramal Enterprises Ltd said on Friday its Dutch unit had signed a deal to divest healthcare analytics business Decision Resources Group to U.S.-based Clarivate Analytics plc for $950 million.

India's Piramal Enterprises raises $246 mln from Canada's CDPQ

Indian conglomerate Piramal Enterprises Ltd said on Thursday it raised 17.50 billion rupees ($246.17 million) via a preferential allotment of compulsory convertible debentures to Canada's Caisse De Depot Et placement Du Quebec (CDPQ).

MEDIA-Piramal said to raise $153 mln for four months from Barclays- Bloomberg

-- Note: Reuters has not verified this story and does not vouch for its accuracy

MEDIA-Piramal Enterprises, Bain Capital's India fund target may be lowered - Mint

- Source link https://www.livemint.com/companies/news/piramal-bain-likely-to-lower-maiden-india-fund-target-to-750-mn-1560446624991.html

BUZZ-India's Torrent Pharmaceuticals sees worst day in 8 months after Q4 loss

** Shares of Torrent Pharmaceuticals Ltd down as much as 7.8% to 1525.35 rupees, their biggest pct loss since Sept. 2018

India's Piramal, Canadian pension fund set up renewable energy trust

Piramal Enterprises Ltd said on Tuesday it had signed a memorandum of understanding with Canada's biggest public pension fund to co-sponsor a $600 million infrastructure trust focused on renewable energy.

BUZZ-India's Piramal Enterprises slips after weak quarterly results

** Shares of Piramal Enterprises Ltd fall as much as 4.32 pct to 2,300 rupees, lowest since Feb. 26

BUZZ-India's DHFL jumps on report Piramal Enterprises may buy stake

** Shares of mortgage lender Dewan Housing Finance Corporation Ltd (DHFL) climb 13.4 pct to 154.8 rupees, their highest since March 6

MEDIA-Piramal Enterprises may re-enter Indian drug market - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

BRIEF-Piramal Enterprises Approves Incorporating Units For Starting Merchant Banking Business

* APPROVED INCORPORATION OF UNIT FOR BUSINESS OF INVESTMENT MANAGER, SPONSOR OF PROPOSED ALTERNATE INVESTMENT FUNDS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up